{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T21:14:12Z","timestamp":1768511652851,"version":"3.49.0"},"posted":{"date-parts":[[2024,4,9]]},"group-title":"Immunology","reference-count":77,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,5,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  Chimeric antigen receptor therapies have demonstrated potent efficacy in treating B cell malignancies, but have yet to meaningfully translate to solid tumors. Here, we utilize our pooled screening platform, CARPOOL, to expedite the discovery of CARs with anti-tumor functions necessary for solid tumor efficacy. We performed selections in primary human T cells expressing a library of 1.3\u00d710\n                  <jats:sup>6<\/jats:sup>\n                  3\n                  <jats:sup>rd<\/jats:sup>\n                  generation CARs targeting IL13R\u03b12, a cancer testis antigen commonly expressed in glioblastoma. Selections were performed for cytotoxicity, proliferation, memory formation, and persistence upon repeated antigen challenge. Each enriched CAR robustly produced the phenotype for which it was selected, and one enriched CAR triggered potent cytotoxicity and long-term proliferation upon\n                  <jats:italic>in vitro<\/jats:italic>\n                  tumor rechallenge. It also showed significantly improved persistence and comparable antigen-specific tumor control in a microphysiological human\n                  <jats:italic>in vitro<\/jats:italic>\n                  model and a xenograft model of human glioblastoma. Taken together, this work demonstrates the utility of extending CARPOOL to diseases beyond hematological malignancies and represents the largest exploration of signaling combinations in human primary cells to date.\n                <\/jats:p>","DOI":"10.1101\/2024.04.04.586240","type":"posted-content","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T10:05:10Z","timestamp":1712657110000},"source":"Crossref","is-referenced-by-count":0,"title":["Pooled screening for CAR function identifies novel IL13R\u03b12-targeted CARs for treatment of glioblastoma"],"prefix":"10.64898","author":[{"given":"Khloe S.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caleb R.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Garmilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxine S.Y.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joey Jy","family":"Aw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anisha","family":"Datta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0050-989X","authenticated-orcid":false,"given":"Douglas A.","family":"Lauffenburger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Pavesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2281-3518","authenticated-orcid":false,"given":"Michael E.","family":"Birnbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024051104301205000_2024.04.04.586240v2.1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","year":"2018","journal-title":"Nat. Rev. Clin. Oncol"},{"key":"2024051104301205000_2024.04.04.586240v2.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1824"},{"key":"2024051104301205000_2024.04.04.586240v2.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00139-y"},{"key":"2024051104301205000_2024.04.04.586240v2.4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41578-021-00394-w","article-title":"Drug delivery to the central nervous system","volume":"7","year":"2021","journal-title":"Nat. Rev. Mater"},{"key":"2024051104301205000_2024.04.04.586240v2.5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20070064"},{"key":"2024051104301205000_2024.04.04.586240v2.6","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.5.2187"},{"key":"2024051104301205000_2024.04.04.586240v2.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1"},{"key":"2024051104301205000_2024.04.04.586240v2.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-683847"},{"key":"2024051104301205000_2024.04.04.586240v2.9","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2446"},{"key":"2024051104301205000_2024.04.04.586240v2.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04390-6"},{"key":"2024051104301205000_2024.04.04.586240v2.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610497"},{"key":"2024051104301205000_2024.04.04.586240v2.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0709"},{"key":"2024051104301205000_2024.04.04.586240v2.13","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4086"},{"key":"2024051104301205000_2024.04.04.586240v2.14","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41590-020-0676-7","article-title":"Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity","volume":"21","year":"2020","journal-title":"Nat. Immunol"},{"key":"2024051104301205000_2024.04.04.586240v2.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0192-1"},{"key":"2024051104301205000_2024.04.04.586240v2.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.05.011"},{"key":"2024051104301205000_2024.04.04.586240v2.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0564-6"},{"key":"2024051104301205000_2024.04.04.586240v2.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2024051104301205000_2024.04.04.586240v2.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133"},{"key":"2024051104301205000_2024.04.04.586240v2.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"2024051104301205000_2024.04.04.586240v2.21","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24"},{"key":"2024051104301205000_2024.04.04.586240v2.22","doi-asserted-by":"crossref","first-page":"662064","DOI":"10.3389\/fnins.2021.662064","article-title":"CAR T cell-based immunotherapy for the treatment of glioblastoma","volume":"15","year":"2021","journal-title":"Front. Neurosci"},{"key":"2024051104301205000_2024.04.04.586240v2.23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4963"},{"key":"2024051104301205000_2024.04.04.586240v2.24","doi-asserted-by":"crossref","first-page":"669071","DOI":"10.3389\/fonc.2021.669071","article-title":"Case report: Prolonged survival following EGFRvIII CAR T cell treatment for recurrent glioblastoma","volume":"11","year":"2021","journal-title":"Front. Oncol"},{"key":"2024051104301205000_2024.04.04.586240v2.25","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw2672"},{"key":"2024051104301205000_2024.04.04.586240v2.26","first-page":"93","article-title":"GD2 CAR T cells against human glioblastoma. NPJ Precis","volume":"5","year":"2021","journal-title":"Oncol"},{"key":"2024051104301205000_2024.04.04.586240v2.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04489-4"},{"key":"2024051104301205000_2024.04.04.586240v2.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2019.07.002"},{"key":"2024051104301205000_2024.04.04.586240v2.29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41392-021-00505-7","article-title":"Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma","volume":"6","year":"2021","journal-title":"Signal Transduct. Target. Ther"},{"key":"2024051104301205000_2024.04.04.586240v2.30","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.3390\/ijms20235942","article-title":"CSPG4 as target for CAR-T-cell therapy of various tumor entities-merits and challenges","volume":"20","year":"2019","journal-title":"Int. J. Mol. Sci"},{"key":"2024051104301205000_2024.04.04.586240v2.31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378"},{"key":"2024051104301205000_2024.04.04.586240v2.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0329-2"},{"key":"2024051104301205000_2024.04.04.586240v2.33","first-page":"855","article-title":"Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains. Nat","volume":"6","year":"2022","journal-title":"Biomed. Eng"},{"key":"2024051104301205000_2024.04.04.586240v2.34","doi-asserted-by":"crossref","first-page":"eabm1463","DOI":"10.1126\/scitranslmed.abm1463","article-title":"Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies","volume":"14","year":"2022","journal-title":"Sci. Transl. Med"},{"key":"2024051104301205000_2024.04.04.586240v2.35","doi-asserted-by":"publisher","DOI":"10.1126\/science.abq0225"},{"key":"2024051104301205000_2024.04.04.586240v2.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34141-8"},{"key":"2024051104301205000_2024.04.04.586240v2.37","doi-asserted-by":"publisher","DOI":"10.1101\/2024.02.26.582129"},{"key":"2024051104301205000_2024.04.04.586240v2.38","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1016\/j.ymthe.2023.09.008","article-title":"Refining chimeric antigen receptors via barcoded protein domain combination pooled screening","volume":"31","year":"2023","journal-title":"Mol. Ther"},{"key":"2024051104301205000_2024.04.04.586240v2.39","doi-asserted-by":"crossref","unstructured":"Brown, C.E. , Hibbard, J.C. , Alizadeh, D. , Blanchard, M.S. , Natri, H.M. , Wang, D. , Ostberg, J.R. , Aguilar, B. , Wagner, J.R. , Paul, J.A. , et al. (2024). Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat. Med., 1\u201312.","DOI":"10.1038\/s41591-024-02875-1"},{"key":"2024051104301205000_2024.04.04.586240v2.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-40055-1"},{"key":"2024051104301205000_2024.04.04.586240v2.41","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/1535-7163.137.3.2","article-title":"Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease","volume":"3","year":"2004","journal-title":"Mol. Cancer Ther"},{"key":"2024051104301205000_2024.04.04.586240v2.42","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2100"},{"key":"2024051104301205000_2024.04.04.586240v2.43","doi-asserted-by":"publisher","DOI":"10.1593\/tlo.11175"},{"key":"2024051104301205000_2024.04.04.586240v2.44","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-006-9220-3"},{"key":"2024051104301205000_2024.04.04.586240v2.45","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/s41467-017-01392-9","article-title":"Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme","volume":"8","year":"2017","journal-title":"Nat. Commun"},{"key":"2024051104301205000_2024.04.04.586240v2.46","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.208"},{"key":"2024051104301205000_2024.04.04.586240v2.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcb.2006.06.004"},{"key":"2024051104301205000_2024.04.04.586240v2.48","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.12.1711"},{"key":"2024051104301205000_2024.04.04.586240v2.49","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478"},{"key":"2024051104301205000_2024.04.04.586240v2.50","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99048"},{"key":"2024051104301205000_2024.04.04.586240v2.51","first-page":"945","article-title":"TGF-\u03b2 signaling and its targeting for glioma treatment","volume":"5","year":"2015","journal-title":"Am. J. Cancer Res"},{"key":"2024051104301205000_2024.04.04.586240v2.52","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2007-010"},{"key":"2024051104301205000_2024.04.04.586240v2.53","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aat6753"},{"key":"2024051104301205000_2024.04.04.586240v2.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.756"},{"key":"2024051104301205000_2024.04.04.586240v2.55","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41392-020-00256-x","article-title":"The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma","volume":"5","year":"2020","journal-title":"Signal Transduct. Target. Ther"},{"key":"2024051104301205000_2024.04.04.586240v2.56","first-page":"vdac140","article-title":"T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells","volume":"4","year":"2022","journal-title":"Neurooncol. Adv"},{"key":"2024051104301205000_2024.04.04.586240v2.57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12464-3"},{"key":"2024051104301205000_2024.04.04.586240v2.58","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202302280"},{"key":"2024051104301205000_2024.04.04.586240v2.59","doi-asserted-by":"crossref","unstructured":"Adriani, G. , and Pavesi, A . (2024). The OrganiX microfluidic system to recreate the complex tumour microenvironment. Nat. Rev. Immunol., 1\u20131.","DOI":"10.1038\/s41577-024-01011-x"},{"key":"2024051104301205000_2024.04.04.586240v2.60","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac185"},{"key":"2024051104301205000_2024.04.04.586240v2.61","doi-asserted-by":"crossref","unstructured":"Bagley, S.J. , Logun, M. , Fraietta, J.A. , Wang, X. , Desai, A.S. , Bagley, L.J. , Nabavizadeh, A. , Jarocha, D. , Martins, R. , Maloney, E. , et al. (2024). Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat. Med., 1\u201310.","DOI":"10.1038\/s41591-024-02893-z"},{"key":"2024051104301205000_2024.04.04.586240v2.62","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2314390"},{"key":"2024051104301205000_2024.04.04.586240v2.63","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0290-5"},{"key":"2024051104301205000_2024.04.04.586240v2.64","doi-asserted-by":"publisher","DOI":"10.1038\/nri2014"},{"key":"2024051104301205000_2024.04.04.586240v2.65","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.omto.2021.08.014","article-title":"Novel two-chain structure utilizing KIRS2\/DAP12 domain improves the safety and efficacy of CAR-T cells in adults with r\/r B-ALL","volume":"23","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"2024051104301205000_2024.04.04.586240v2.66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3417"},{"key":"2024051104301205000_2024.04.04.586240v2.67","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003050"},{"key":"2024051104301205000_2024.04.04.586240v2.68","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ymthe.2020.08.016","article-title":"T cells expressing NKG2D CAR with a DAP12 signaling domain stimulate lower cytokine production while effective in tumor eradication","volume":"29","year":"2021","journal-title":"Mol. Ther"},{"key":"2024051104301205000_2024.04.04.586240v2.69","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400330"},{"key":"2024051104301205000_2024.04.04.586240v2.70","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CJI.0000000000000082","article-title":"Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12\/SDF-1\u03b1-secreting glioblastoma","volume":"38","year":"2015","journal-title":"J. Immunother"},{"key":"2024051104301205000_2024.04.04.586240v2.71","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2217\/imt-2019-0017","article-title":"TREM1\/Dap12-based CAR-T cells show potent antitumor activity","volume":"11","year":"2019","journal-title":"Immunotherapy"},{"key":"2024051104301205000_2024.04.04.586240v2.72","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-168245"},{"key":"2024051104301205000_2024.04.04.586240v2.73","doi-asserted-by":"publisher","DOI":"10.1038\/nri2434"},{"key":"2024051104301205000_2024.04.04.586240v2.74","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj2820"},{"key":"2024051104301205000_2024.04.04.586240v2.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.05.031"},{"key":"2024051104301205000_2024.04.04.586240v2.76","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-018-1603-1"},{"key":"2024051104301205000_2024.04.04.586240v2.77","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2021.04.048"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.04.04.586240","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:15:23Z","timestamp":1768457723000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.04.04.586240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,9]]},"references-count":77,"URL":"https:\/\/doi.org\/10.1101\/2024.04.04.586240","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1136\/jitc-2024-009574","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,4,9]]},"subtype":"preprint"}}